Soria JC, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113-25.,Ramalingam SS, et al. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. Abstract LBA5_PR. ESMO Congress 2019, Barcelona, Spanje.
KiKa-subsidie voor LUMC-onderzoek naar nierkanker bij kinderen
jul 2021 | Uro-oncologie